LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 82

Search options

  1. Article ; Online: Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.

    Paneesha, S / Pratt, G / Parry, H / Moss, P

    Leukemia research

    2020  Volume 93, Page(s) 106366

    MeSH term(s) Aged ; Aged, 80 and over ; Betacoronavirus ; COVID-19 ; Coronavirus Infections/pathology ; Female ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/complications ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Lymphocyte Count ; Lymphocytosis/etiology ; Male ; Middle Aged ; Pandemics ; Pneumonia, Viral/pathology ; SARS-CoV-2 ; Watchful Waiting/methods
    Keywords covid19
    Language English
    Publishing date 2020-04-30
    Publishing country England
    Document type Case Reports ; Letter
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2020.106366
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia

    Paneesha, S. / Pratt, G. / Parry, H. / Moss, P.

    Leukemia Research

    2020  Volume 93, Page(s) 106366

    Keywords Cancer Research ; Oncology ; Hematology ; covid19
    Language English
    Publisher Elsevier BV
    Publishing country us
    Document type Article ; Online
    ZDB-ID 752396-8
    ISSN 1873-5835 ; 0145-2126
    ISSN (online) 1873-5835
    ISSN 0145-2126
    DOI 10.1016/j.leukres.2020.106366
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1321: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.

    Paneesha, Shankara / Pratt, Guy / Parry, Helen / Moss, Paul

    2020  

    Keywords QZ Pathology. Oncology ; WF Respiratory system. Respiratory medicine ; WH Haemic and lymphatic systems. Haematology ; covid19
    Publishing date 2020-04-30
    Publisher Elsevier
    Publishing country uk
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  5. Article ; Online: Covid-19 infection in therapy-naive patients with B-cell chronic lymphocytic leukemia.

    Paneesha, Shankara / Pratt, Guy / Parry, Helen / Moss, Paul

    2020  

    Keywords QZ Pathology. Oncology ; covid19
    Language English
    Publisher Pergamon Press
    Publishing country uk
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  6. Article: Imbruvica

    Murthy, Vidhya / Weaving, Susan / Paneesha, Shankara

    British journal of nursing (Mark Allen Publishing)

    2017  Volume 26, Issue 10, Page(s) S20–S25

    Abstract: Single-agent ibrutinib is an effective therapy for three types of non-Hodgkin lymphoma: chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma, both in relapsed and refractory cases and as a frontline treatment; relapsed and refractory mantle ...

    Abstract Single-agent ibrutinib is an effective therapy for three types of non-Hodgkin lymphoma: chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma, both in relapsed and refractory cases and as a frontline treatment; relapsed and refractory mantle cell lymphoma; and Waldenstrom's macroglobulinaemia in patients who have been treated previously with a different medication. This novel agent has changed the landscape for the aforementioned three subtypes of lymphoma therapies as an oral alternative to traditional chemoimmunotherapy. You&i™ is a no-cost support programme, funded by Janssen, that connects patients taking Imbruvica with a nurse who can answer their questions and help address treatment challenges. This programme offers patients information about their disease, their treatment regimen and side effects management by telephone. The You&i programme was tested at an NHS hospital. Case studies of patients and feedback from health professionals who have used this service show its potential benefits to the patient experience and service delivery.
    MeSH term(s) Agammaglobulinaemia Tyrosine Kinase ; Aged ; Antineoplastic Agents/therapeutic use ; Drug Industry ; Humans ; Leukemia, Lymphocytic, Chronic, B-Cell/drug therapy ; Leukemia, Lymphocytic, Chronic, B-Cell/nursing ; Lymphoma, Mantle-Cell/drug therapy ; Lymphoma, Mantle-Cell/nursing ; Lymphoma, Non-Hodgkin/drug therapy ; Lymphoma, Non-Hodgkin/nursing ; Male ; Nurses ; Patient Education as Topic ; Protein-Tyrosine Kinases/antagonists & inhibitors ; Pyrazoles/therapeutic use ; Pyrimidines/therapeutic use ; State Medicine ; Telephone ; United Kingdom
    Chemical Substances Antineoplastic Agents ; Pyrazoles ; Pyrimidines ; ibrutinib (1X70OSD4VX) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Agammaglobulinaemia Tyrosine Kinase (EC 2.7.10.2)
    Language English
    Publishing date 2017-05-23
    Publishing country England
    Document type Journal Article
    ZDB-ID 1119191-0
    ISSN 0966-0461
    ISSN 0966-0461
    DOI 10.12968/bjon.2017.26.10.S20
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3449: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: ERRATUM: A unique case of durable complete remission after salvage with azacitidine and DLI for high risk flt-3 positive acute myeloid leukemia, following relapse 18 months post allogeneic stem cell transplant.

    Horgan, Claire / Kanellopoulos, Alexandros / Paneesha, Shankara / Kishore, Bhuvan / Lovell, Richard / Nikolousis, Emmanouil

    Hematology reports

    2020  Volume 12, Issue 2, Page(s) 8995

    Language English
    Publishing date 2020-11-16
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 2586645-X
    ISSN 2038-8330 ; 2038-8322
    ISSN (online) 2038-8330
    ISSN 2038-8322
    DOI 10.4081/hr.2020.8995
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Parsaclisib, a PI3Kδ inhibitor, in relapsed and refractory follicular lymphoma (CITADEL-203): a phase 2 study.

    Trněný, Marek / Avigdor, Abraham / McKinney, Matthew S / Paneesha, Shankara / Wahlin, Björn E / Hrom, John S / Cunningham, David / Morley, Nicholas / Canales, Miguel / Bastos-Oreiro, Mariana / Belada, David / Devizzi, Liliana / Zheng, Fred / DeMarini, Douglas J / Jiang, Wei / Jiang, Ping / Lynch, Ryan C

    EClinicalMedicine

    2023  Volume 63, Page(s) 102130

    Abstract: Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy ...

    Abstract Background: Parsaclisib, a potent and highly selective PI3Kδ inhibitor, has shown clinical benefit in patients with relapsed or refractory (R/R) B-cell malignancies. This phase 2 study (CITADEL-203; NCT03126019, EudraCT 2017-001624-22) assessed efficacy and safety of parsaclisib monotherapy in patients with R/R follicular lymphoma (FL).
    Methods: Patients ≥18 years of age with histologically confirmed R/R FL (grade 1-3a) and prior treatment with ≥2 systemic therapies received parsaclisib 20 mg once daily (QD) for 8 weeks then parsaclisib 20 mg once weekly (weekly dosing group [WG]) or parsaclisib 20 mg QD for 8 weeks then parsaclisib 2.5 mg QD (daily dosing group [DG]); DG was selected for further assessment. Primary endpoint was objective response rate (ORR).
    Findings: At data cut-off (January 15, 2021), 126 patients had been treated (WG: n = 23; DG: n = 103). ORR (95% confidence interval [CI]) was 77.7% (68.4-85.3) with a complete response rate (95% CI) of 19.4% (12.3-28.4) in DG; median (95% CI) duration of response was 14.7 months (10.4-not estimable [NE]), median progression-free survival was 15.8 months (11.0-NE), and median overall survival was not reached. The most common any-grade treatment-emergent adverse events (TEAEs) among all treated patients included diarrhoea (n = 48, 38.1%), nausea (n = 31, 24.6%), and cough (n = 28, 22.2%); the most common grade ≥3 TEAEs were diarrhoea (n = 15, 11.9%), neutropenia (n = 13, 10.3%), and colitis (n = 7, 5.6%). Dose interruption, reduction, and discontinuation from TEAEs occurred in 46.8% (n = 59), 17.5% (n = 22), and 23.8% (n = 30) of patients, respectively.
    Interpretation: Treatment with parsaclisib demonstrated rapid and durable responses, and a manageable safety profile in patients with R/R FL.
    Funding: Incyte Corporation.
    Language English
    Publishing date 2023-08-18
    Publishing country England
    Document type Journal Article
    ISSN 2589-5370
    ISSN (online) 2589-5370
    DOI 10.1016/j.eclinm.2023.102130
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  9. Article: Adenoviral Subacute Focal Meningoencephalitis Complicating Polatuzumab, Bendamustine and Rituximab Chemo-Immunotherapy for Aggressive B-Cell Lymphoma.

    Chander, Gurvin / Nikolousis, Emmanouil / Osman, Husam / Shirley, Ellen / Kishore, Bhuvan / Lovell, Richard / Mistry, Jayna / Paneesha, Shankara / Kanellopoulos, Alexandros

    Indian journal of hematology & blood transfusion : an official journal of Indian Society of Hematology and Blood Transfusion

    2021  Volume 38, Issue 1, Page(s) 184–186

    Language English
    Publishing date 2021-06-16
    Publishing country India
    Document type Journal Article
    ZDB-ID 2422370-0
    ISSN 0974-0449 ; 0971-4502
    ISSN (online) 0974-0449
    ISSN 0971-4502
    DOI 10.1007/s12288-021-01456-3
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Ibrutinib as part of risk-stratified treatment for post-transplant lymphoproliferative disorder: The phase 2 TIDaL trial.

    Chaganti, Sridhar / Maycock, Shanna / McIlroy, Graham / Jackson, Aimee E / Bishop, Rebecca / Johnson, Sarah / Kanfer, Edward / Kassam, Shireen / Cwynarski, Kate / Wrench, David J / Arumainathan, Arvind / Fox, Christopher P / Johnson, Rod J / McKay, Pamela / Paneesha, Shankara / Rowntree, Clare / Balotis, Constantine / Collins, Graham P / Davies, Andrew J /
    Wright, Josh / Burns, Sarah / Laurence, Arian Dominic John / Wheatley, Keith / Menne, Tobias

    Blood

    2024  

    Abstract: Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified ... ...

    Abstract Post-transplant lymphoproliferative disorder (PTLD) is a rare complication of solid organ transplantation, and cytotoxic chemotherapy is associated with treatment-related morbidity and mortality. Current treatment takes a sequential, risk-stratified approach, patients with low-risk disease following initial immunotherapy can avoid escalation to immunochemotherapy. TIDaL is a prospective, single-arm phase 2 trial investigating the activity and tolerability of ibrutinib combined with risk-stratified therapy for first-line treatment of PTLD. Eligible patients were adults with newly-diagnosed CD20-positive B-cell PTLD after solid organ transplant and performance status 0 to 2. Initial treatment comprised 49 days of ibrutinib 560mg once daily, with 4 doses of weekly rituximab. Treatment response on interim scan and baseline international prognostic index were used to allocate patients to either a low-risk arm (who continued ibrutinib, alongside 4 further doses of 3-weekly rituximab) or high-risk (escalation to R-CHOP immunochemotherapy, ibrutinib continuing in patients aged <65 years). The primary outcome was complete response on interim scan, achieved by 11/38 patients (29%, 95% confidence interval (CI) 15% - 46%). This did not reach the pre-specified threshold for clinically significant activity. Secondary outcomes included allocation to the low-risk arm (41% of patients), 2-year progression-free survival (58%, 95% CI 44% - 76%), and 2-year overall survival (76%, 95% CI 63% - 91%). Adverse events were mostly haematological, gastrointestinal and infective. Whilst TIDaL does not support adding ibrutinib into first-line treatment of PTLD, increasing the proportion of patients who can be treated without cytotoxic chemotherapy remains an important aim of future research. This trial was registered as ISRCTN32667607.
    Language English
    Publishing date 2024-04-21
    Publishing country United States
    Document type Journal Article
    ZDB-ID 80069-7
    ISSN 1528-0020 ; 0006-4971
    ISSN (online) 1528-0020
    ISSN 0006-4971
    DOI 10.1182/blood.2024023847
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Uh III Zs.140: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 364: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top